Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05377216

Enrollment

Registered

2022-05-17

Start date

2022-09-01

Completion date

2027-07-01

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia

Brief summary

Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.

Interventions

DRUGStellate Ganglion Block

Left sided percutaneous stellate ganglion block

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Planned catheter based VT ablation * Age at least 18 years

Exclusion criteria

* Pregnancy * Contraindication to SGB or VT ablation * Hypersensitivity of local anesthetic of amide type * Hemodynamic instability during the procedure prior to the study protocol

Design outcomes

Primary

Measure	Time frame	Description
Ventricular Effective Refractory Period	30 minutes following stellate ganglion block	Change in Ventricular Effective Refractory Period at 600ms drive train (measured in milliseconds)

Secondary

Measure	Time frame	Description
Ventricular Arrhythmia Inducibility	30 minutes following stellate ganglion block	Induction of monomorphic ventricular arrhythmia (binary outcome) during ventricular programmed stimulation
Neuropeptide Y	30 minutes following stellate ganglion block	Change in level of neuropeptide Y from baseline (measured in pg/mL)

Countries

United States

Contacts

Primary ContactTimothy Markman, MD

timothy.markman@pennmedicine.upenn.edu267-593-0103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026